Annals of Oncology 7:S79-S84, 1996
© 1996 European Society for Medical Oncology
Reviews |
Management of early stage Hodgkin's disease: The role of radiation therapy and/or chemotherapy
Joint Center for Radiation Therapy, Department of Radiation Therapy, Harvard Medical School Boston, MA, U.S.A.
Correspondence to: Peter M. Mauch, M.D. JCRT 50 Binney Street Boston, MA 02115 U.S.A.
Clinical trials in early stage Hodgkin's disease comparing radiation therapy (RT) alone versus chemotherapy (CMT) have indicated fewer relapses in the CMT groups. However, none of the trials have demonstrated an overall survival difference. Risk factors for relapse in early stages include large mediastinal adenopathy, fevers, and weight loss. Ongoing clinical trials might prove less toxic CMT effective in curing occult microscopic disease, perhaps eventually obviating the need for staging laparotomy and splenectomy.
early stages, Hodgkin's disease, radiation therapy, prognostic factors, splenectomy